• 1
    Sherlock S, Dooley J. The haematology of liver disease. In: Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Scientific, 1993; 4547.
  • 2
    Meijer DKF, Weert B, Vermer GA. Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. Eur J Clin Pharmacol 1988; 35: 295303.
  • 3
    Hacki W, Bircher J, Preisig R. A new look at the plasma disappearance of sulfobromophthalein (BSP): correlation with the BSP transport maximum and the hepatic plasma flow in man. J Lab Clin Med 1976; 88: 10191031.
  • 4
    St Peters JV, Awni WM. Quantifying hepatic function in the presence of liver disease with Phenazone (Antipyrine) and its metabolites. Clin Pharmacokinet 1991; 20: 5065.
  • 5
    Bircher J. Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis 1983; 3: 275284.
  • 6
    Wahllender A, Mohr S, Paumgartner G. Assessment of hepatic function: comparison of caffeine clearance in serum and saliva during day and night. J Hepatol 1990; 10: 129137.
  • 7
    Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450: studies in rats and patients. J Clin Invest 1989; 83: 688697.
  • 8
    Galizzi J, Long RG, Billing BH, Sherlock S. Assessment of the (14C)aminopyrine breath test in liver disease. Gut 1978; 19: 4045.
  • 9
    Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978; 3: 177201.
  • 10
    Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989; 46: 521527.
  • 11
    Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a Cytochrome P450 III gene family as the major cyclosporine-metabolising enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630635.
  • 12
    Combalbert J, Fabre I, Fabre G, Dalat I, Derancourt J, Cano JP, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450 IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197207.
  • 13
    Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753761.
  • 14
    Oellerich M, Raude E, Burdelski M, Schulz M, Schmidt FW, Ringe B, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987; 25: 845853.
  • 15
    Oellerich M, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann HTI. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990; 12: 219226.
  • 16
    Zoth RB, Muller T, Erhard J, Lange R, Beste M, von Schonfeld J, et al. Quantitative liver function tests and donor specific factors in the prediction of early postoperative graft function. Lab Med 1994; 18: 439440.
  • 17
    Potter JM, Wright M, Lynch SV, Strong RW, Henderson A, Balderson G, et al. Lignocaine metabolism and liver function testing in primary graft failure following orthotopic liver transplantation. Med J Aust 1993; 158: 125126.
  • 18
    Vickers AE, Fischer V, Connors S, Fisher RL, Baldeck JP, Maurer G, et al. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos 1902; 20: 802809.
  • 19
    Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Evidence for pre-hepatic metabolism of oral cyclosporine in children. Brit J Clin Pharmacol 1991; 32: 477481.
  • 20
    Kolars JC, Awni WM, Merion RM, Watkins PB. First pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 14881490.
  • 21
    Oellerich M, Burdelski M, Ringe B, Ozaki N, Binder L, Pichlmayr R. Assessment of donor organ function. In: Therapy in liver diseases. RodesJ, ArroyaV, eds. Edicion Doyna, 1992; 227236.
  • 22
    Sallie RW, Tredger JM, Williams R. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX). Biopharm Drug Dispos 1992; 13: 555558.
  • 23
    Chen Y, Potter JM. Fluorescence polarization immunoassay and HPLC assays compared for measuring monoethylglycinexylidide in liver-transplant patients. Clin Chem 1992; 38: 24262430.
  • 24
    Zoppi F, Fumagalli C. Improved measurement of MEGX in serum with the abbott TDx [letter]. Clin Chem 1992; 38: 441442.
  • 25
    Evans RW. The demand for transplantation in the United States. In: TerasakiP, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1990; 319327.
  • 26
    Shaw BM Jr, Wood RP, Gordon RD, Iwatsuki S, Gillquist WP, Starzl TE. Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. Semin Liver Dis 1985; 5: 385393.
  • 27
    Oellerich M, Burdelski M, Lautz HU, Binder L, Pichlmayr RTI. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991; 14: 10291034.
  • 28
    Oellerich M, Burdelski M, Lautz HU, Rodeck B, Duewel J, Schulz M, et al. Assessment of pretransplant prognosis in patients with cirrhosis. Transplantation 1991; 51: 801806.
  • 29
    Burdelski M, Oellerich M, Duewel J, Raith H, Scheruhn M, Ringe B, et al. Pre- and posttransplant assessment of liver function in pediatric liver transplantation. Eur J Pediatr 1992; 151(suppl 1): 3945.
  • 30
    Gremse DA, A-Kader HH, Schroeder TJ, Balistreri WFTI. Assessment of lidocaine metabolite formation as a quantitative liver function test in children. Hepatology 1990; 12: 565569.
  • 31
    Shiffman ML, Fisher RA, Sanyal AJ, Edinboro LE, Luketic VA, Purdum PP III, et al. Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation. Transplantation 1993; 55: 830835.
  • 32
    Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, et al. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19: 140147.
  • 33
    Arrigoni A, Gindro T, Aimo G, Capello N, Meloni A, Benedetti P, et al. Monoethylglycinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology 1994; 20: 383387.
  • 34
    Luketic VA, Shiffman ML, Fisher RA, Sanyal AJ, Purdrum PP III, Posner MP. Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation. Transplant Proc 1993; 25: 10721074.
  • 35
    Waters B, Adamec TA, Smalley DL, Karas JG, Flynn PM, Relling MV, et al. Use of lidocaine metabolism to quantify liver function in chronic hepatitis C [abstract]. Hepatology 1991; 14: 164A.
  • 36
    Marcucci L, Grant S, Samuel SE, Munoz SJ, Zakhireh B, Gibson W, et al. The monoethylglycinexylidide (MEGX) formation test versus prothrombin time and total bilirubin as a predictor of hepatic encephalopathy [abstract]. Hepatology 1992; 16: 250A.
  • 37
    Meyer-Wyss B, Renner E, Luo H, Scholer ATI. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol 1993; 19: 133139.
  • 38
    Oellerich M, Schutz E, Polzien F, Ringe B, Armstrong VW, Hartmann H, et al. Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors. Ther Drug Monit 1994; 16: 225231.
  • 39
    Oellerich M, Hartmann H, Ringe B, Burdelski M, Lautz HU, Pichlmayr R. Assessment of prognosis in transplant candidates by use of the Pugh-MEGX score. Transplant Proc 1993; 25: 11161119.
  • 40
    d'Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, et al. The predictive value of donor liver biopsy on the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991; 51: 157163.
  • 41
    Kazikoe S, Yanaga K, Starzl TE, Demetrius AJ. Evaluation of the protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: consideration of preservation and early immunilogical injury. Hepatology 1990; 11: 932942.
  • 42
    Mor E, Klintmalm GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, et al. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 1992; 53: 383386.
  • 43
    Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, et al. Frozen section evaluation of donor livers before transplantation. Transplantation 1993; 56: 14031409.
  • 44
    Oellerich M, Burdelski M, Ringe B, Wittekind Ch, Lamesch P, Lautz HU, et al. Functional state of the donor liver and early outcome of transplantation. Transplant Proc 1991; 23: 15751578.
  • 45
    Oellerich M, Burdelski M, Ringe B, Lamesch P, Gubernatis G, Bunzendahl H, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; 1: 640642.
  • 46
    Adam R, Azoulay D, Astarcioglu I, Chiche L, Bao YM, Bonhomme L, et al. Limits of the MEGX test in the selection of liver grafts for transplantation. Transplant Proc 1993; 25: 16531654.
  • 47
    Adam R, Azoulay D, Astarcioglu I, Bao YM, Bonhomme L, Fredj G, et al: Reliability of the MEGX test in the selection of liver grafts. Transplant Proc 1991; 23: 24702471.
  • 48
    Potter JM, Balderson GA, Hickman PE, Henderson A, Wright M, Burrow B, et al. The value of the donor MEGX test in predicting liver allograft recipient outcome. Transplantation 1994; 58: 524526.
  • 49
    Potter JM, Hickman PE, Balderson G, Lynch SV, Strong A. Lignocaine metabolism and MEGX production in the liver transplant donor. Transplant Proc 1992; 24: 198199.
  • 50
    Balderson GA, Potter JM, Hickman PE, Chen Y, Lynch SV, Strong RW. MEGX as a test of donor liver function. Transplant Proc 1992; 24: 19601961.
  • 51
    Karayalcin K, Mirza DF, Harrison RF, da Silva RF, Hubscher SJ, Mayer AD, et al. The role of dynamic and morphological studies in the assessment of potential liver donors. Transplantation 1994; 57: 13231327.
  • 52
    Tesi RJ, Elkhammas EA, Davies EA, Salazar A, Henry ML, Greenson J, et al. Safe use of liver donors with MEGX values less than 90 ng/mL. Transplant Proc 1993; 25: 16551656.
  • 53
    Contis IC, Heffron TG, Whitington SH, Whitington PF, Emond JC. Assessment of donor liver function and early outcome of liver transplantation with the use of MEGX test [abstract]. Hepatology 1992; 16: 276A.
  • 54
    Schroeder TJ, Pesce AJ, Ryckman FC, Tressler TP, Brunson ME, Pedersen SH, et al. Selection criteria for liver transplant donors. J Clin Lab Anal 1991; 5: 275277.
  • 55
    Reding R, Wallemacq P, de Ville de Goyet J, Lerut J, Hausleithner V, Feyaerts A, et al. The unreliability of the lidocaine/monoethylglycinexylidide test for assessment of liver donors. Transplantation 1993; 56: 323326.
  • 56
    Bruzzone P, Alfani D, Rossi M, Berloco P, Cortesini R. Monoethylglycinexylidide clearance test: its role as a part of brain-dead donors' evaluation for liver transplantation. Transplant Proc 1993; 25: 31123113.
  • 57
    Michell ID, Abdulnour I, Pzybylowski G, Bowkett J, Gleeson A, Hardy KJ, et al. Donor hyaluronic acid and MEGX levels do not accurately predict posttransplant liver function. Transplant Proc 1993; 25: 28882889.
  • 58
    Rosenlof LK, Sawyer RG, Broccoli AV, Ishitani MB, Stevenson WC, Pruett TL. Histological comparison of donor livers and lidocaine metabolism in the utilization of organs for liver transplantation. Transplant Proc 1993; 25: 16621663.
  • 59
    Van Lente F, Bratush JR. Measurement of monoethylglycinexylidide (MEGX) as an index of donor liver function: a practical experience [abstract]. Ther Drug Monit 1993; 15: 147A.
  • 60
    Oellerich M. Current status of the use of liver function tests in transplantation. In: III Simposio Nazionale, Monitororaggio Farmaci e Dreghe D'Abuso. 1992: 5467.
  • 61
    Ploeg RJ, d'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffman RM, et al. Risk factors for primary dysfunction after liver transplantation—a multivariate analysis. Transplantation 1993; 55: 807813.
  • 62
    Sherlock S, Dooley J. Hepatocellular failure. In: Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Scientific, 1993; 7778.
  • 63
    Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20: 306316.
  • 64
    Lehmann V, Oellerich M, Pape D, Sturm JA, Regel G. Assessment of liver function in multiple trauma patients using the MEGX test. In: Gall FP, BergerHG, UngeheuerE, eds. Chirugisches Forum 1992 f. experim. u. klinische Forschung. Berlin Heidelberg: Springer Verlag, 1993; 437440.
  • 65
    Rossi SJ, Schroeder TJ, Vine WH, A-Kader HH, Gremse DA, Ryckman FC, et al. Monoethylglycinexylide formation in assessing pediatric donor liver function. Ther Drug Monit 1992; 14: 452456.
  • 66
    Balderson GA, Potter JM, Hickman PE, Lynch SV, Strong RW. The role of MEGX in liver transplantation [abstract]. Proc Transplant Soc Aust NZ 1994; 12: 48A.
  • 67
    Mets B, Hickman R, Allin R, Van Dyk J, Lotz Z. Effect of hypoxia on the hepatic metabolism of lidocaine in the isolated perfused pig liver. Hepatology 1993; 17: 668676.
  • 68
    Ratanasavanh D, Beaune P, Morel F, Flinois JP, Guengerich FP, Guillouzo A. Intralobular distribution and quantitation of Cytochrome P-450 enzymes in human liver as afunction of age. Hepatology 1991; 13: 11421151.
  • 69
    Murray GI, Barnes TS, Sewell HF, Ewen SW, Melvin WT, Burke MD. The immunochemical localization and distribution of cytochrome P-450 in normal hepatic and extrahepatic tissues with a monoclonal antibody to cytochrome P-450. Br J Clin Pharmacol 1988; 25: 465475.
  • 70
    Lemoine A, Azoulay D, Gries JM, Dennison A, Castaing D, Fredj G, et al. Relationship between graft Cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation 1993; 56: 14101414.
  • 71
    Diaz D, Pageaux GP, Fabre JM, Pichard L, Maurel P, Baumel H, et al. The risk of short-term liver graft dysfunction may be correlated with low pre-transplant hepatic cytochrome P-450 IIIA4 level [abstract]. J Hepatol 1990; 11(Suppl 2): S19A.
  • 72
    Devlin JJ, O'rady JG, Tan KC, Calne RY, Williams R. Ethnic variations in patient and graft survival after liver transplantation. Identification of a new risk factor for chronic allograft rejection. Transplantation 1993; 56: 13811384.
  • 73
    Kennedy EM, Wood RP, Shaw BW. Primary non function: is there a contribution from the back table? Transplantation 1990; 49: 739743.
  • 74
    Burdelski M, Oellerich M, Bornscheuer A, Luebbe N, Ringe B, Lamesch P, et al. Donor rating in human liver transplantation: correlation of oxygen consumption after revascularization with MEGX formation in donors. Transplant Proc 1989; 21: 23922393.
  • 75
    Potter JM, Hickman PE, Lynch SV, Henderson A, Wright M, Balderson G, et al. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient. Transplantation 1993; 56: 13851388.
  • 76
    Schroeder TJ, Gremse DA, Mansour ME, Theuerling AW, Brunson ME, Ryckman FC, et al. Lidocaine metabolism as an index of liver function in hepatic transplant donors ands recipients. Transplant Proc 1989; 21: 22992301.
  • 77
    Schutz E, Kaltefleiter M, Luy-Kaltefleiter M, Ringe B, Armstrong VW, Burdelski M, et al. Prediction of early graft survival and complications by serial determination of MEGX and hyaluronic acid after OLT [abstract]. Hepatology 1994; 20: 126A.
  • 78
    Oellerich M, Burdelski M, Beyrau R, Ringe B, Lamesch P, Wonogeit K, et al. Lidocaine metabolite formation as a measure of early post-transplant liver function [abstract]. Hepatology 1989; 10: 625A.
  • 79
    Oellerich M, Schutz E, Kaltefleiter M, Luy M, Winkler M, Wonigeit K, et al. FK 506 and cyclosporin compared with regard to early post-transplant liver function [abstract]. Ther Drug Monit 1993; 15: 146.
  • 80
    Schutz E, Luy-Kaltefleiter M, Kaltefleiter M, Burdelski M, Ringe B, Armstrong VW, et al. Prediction of allograft survival and complications by serial determination of MEGX and hyaluronic acid early after orthotopic liver transplantation. Liver Transplant Surg (submitted).
  • 81
    Potter JM, Hickman PE, Chen Y, Henderson A, Wright M, Lynch SV, et al. MEGX in hepatic artery thrombosis and ischaemia following liver transplantation [abstract]. Ther Drug Monit 1993; 15: 125.
  • 82
    Potter JM, Hickman PE, Chen Y, Scott C, Lynch SV, Strong R. Lignocaine metabolism as a test of liver function in liver transplant recipients. In: MiyaiK, KannoT, IshikawaE, eds. Progress in Clinical Biochemistry. Elsevier Science Publishers BV, 1992; 10491051.
  • 83
    Erhard J, Hartwig T, Lange R, Scherer R, Albrecht KM, Eigler FW. The value of duplex sonography after orthotopic liver transplantation. Experience with 44 patients. Langenbecks Arch chir 1994; 379: 2631.
  • 84
    Hickman PE, Lynch SV, Potter JM, Walker NI, Strong RW, Clouston AD. Gamma glutamyl transferase as a marker of liver transplant rejection. Transplantation 1994; 57: 12781280.
  • 85
    Calmus Y, Conti F, Dousset B, Guerin C, Cherruau B, Abbas A, et al. Assessment of liver function by lidocaine metabolism (MEGX formation) one year after liver transplantation [abstract]. Hepatology 1993; 17: 326A.
  • 86
    Henry ML, Tesi RJ, Elkhannas EA, Ferguson RM. Trial of Cyclosporine vs Og37–325 in cadaveric renal transplantation: a preliminary report. Transplant Proc 1993; 25: 689690.
  • 87
    Christians U, Kohlhaw K, Esselmann H, Surig T, Luy M, Kaltefleiter M, et al. The yin and yang of lidocaine and cyclosporine metabolism in liver graft recipients. Transplant Proc 1994; 26: 28272828.